Phase 3 Recruiting Industry
The purpose of this study is to evaluate the safety and efficacy of a novel RAS(ON) inhibitor compared to standard of care (SOC) observation only.
Sponsor: Revolution Medicines, Inc.
NCT ID: NCT07252232
Sites in Indiana: - Community Health Network — Indianapolis, Indiana
Phase 1, Phase 2 Recruiting Network
This phase I/II trial evaluates the highest safe dose, side effects, and possible benefits of tegavivint in treating patients with solid tumors that has come back (recurrent) or does not respond to treatment (refractory). Tegavivint interf…
Sponsor: Children's Oncology Group
NCT ID: NCT04851119
Sites in Indiana: - Riley Hospital for Children — Indianapolis, Indiana
Phase 1, Phase 2 Recruiting Industry
TNG462-C102 is a Phase 1/2, open-label, multicenter study designed to determine the safety, tolerability, PK, PD, and preliminary antineoplastic activity of oral TNG462 in combination with RMC-6236, RMC-9805, mFOLFIRINOX or gemcitabine/nab…
Sponsor: Tango Therapeutics, Inc.
NCT ID: NCT06922591
Sites in Indiana: - University of Indiana — Indianapolis, Indiana
Phase 1, Phase 2 Recruiting Industry
The goal of this clinical trial is to evaluate FMC-376 in participants with advanced solid tumors with KRAS G12C mutations. This clinical trial will be conducted in 3 parts: Phase 1A (Dose Escalation), Phase 1B (Dose Expansion), and Phase …
Sponsor: Frontier Medicines Corporation
NCT ID: NCT06244771
Sites in Indiana: - Northwest Cancer Centers — Dyer, Indiana
Phase 1 Recruiting Industry
This trial will look at a drug called sigvotatug vedotin (SGN-B6A) alone and with pembrolizumab, with or without chemotherapy, to find out whether it is safe for people who have solid tumors. It will study sigvotatug vedotin to find out wh…
Sponsor: Seagen, a wholly owned subsidiary of Pfizer
NCT ID: NCT04389632
Sites in Indiana: - UChicago Medicine - Northwest Indiana — Crown Point, Indiana
- Fort Wayne Medical Oncology and Hematology, Inc — Fort Wayne, Indiana
- Community Health Network, Inc — Indianapolis, Indiana
- Community Health Network, Inc. — Indianapolis, Indiana
- Community Health Network Investigational Drug Services — Indianapolis, Indiana
Phase 1 Recruiting Industry
The main purpose of this study is to assess safety \& tolerability and antitumor activity of LY3962673 as monotherapy and in combination with other chemotherapy agents in participants with KRAS G12D-mutant advanced solid tumor types. The s…
Sponsor: Eli Lilly and Company
NCT ID: NCT06586515
Sites in Indiana: - Community Health Network — Indianapolis, Indiana
Phase 1 Recruiting Industry
The purpose of this study is to find out whether the study drug, LY4052031, is safe, tolerable and effective in participants with advanced, or metastatic solid tumors including urothelial cancer. The study is conducted in two parts - phase…
Sponsor: Eli Lilly and Company
NCT ID: NCT06465069
Sites in Indiana: - IU Simon Cancer Center — Indianapolis, Indiana
Phase 1 Recruiting Industry
Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. Non-Small Cell Lung Cancer (NSCLC) is a solid tumor, a disease in which cancer cells form in the tissues of the lung. Head and Neck Squamous Ce…
Sponsor: AbbVie
NCT ID: NCT05005403
Sites in Indiana: - Fort Wayne Medical Oncology and Hematology, Inc /ID# 232593 — Fort Wayne, Indiana
- Community Health Network, Inc. /ID# 243011 — Indianapolis, Indiana
Phase 1 Recruiting Industry
This is a study of LY4337713 in participants with certain types of cancer that is advanced or has spread. Participants must have cancer with high levels of a protein called fibroblast activation protein (FAP). The purpose of this study is …
Sponsor: Eli Lilly and Company
NCT ID: NCT07213791
Sites in Indiana: - Indiana University (IU) School of Medicine — Indianapolis, Indiana
Phase 1 Recruiting Industry
This is an open label, multi-center, multiple dose Phase 1 study to evaluate the safety, tolerability, MTD PK, and PD of TJ033721 (givastomig) in subjects with advanced or metastatic solid tumors.
Sponsor: I-Mab Biopharma US Limited
NCT ID: NCT04900818
Sites in Indiana: - Horizon Oncology Research, LLC. — Layfayette, Indiana
Recruiting Academic/Other
This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in th…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT05334069
Sites in Indiana: - Reid Health — Richmond, Indiana
Recruiting Network
The purpose of this study is to compare two approaches for monitoring pancreatic cysts as well as to identify associated biomarkers. The study doctors want to compare more frequent monitoring versus less frequent monitoring as well as iden…
Sponsor: ECOG-ACRIN Cancer Research Group
NCT ID: NCT04239573
Sites in Indiana: - Indiana University/Melvin and Bren Simon Cancer Center — Indianapolis, Indiana
- Reid Health — Richmond, Indiana
Recruiting Academic/Other
This study evaluates cancer-related weight and muscle mass loss, symptoms, and physical function (cachexia) in patients undergoing treatment for colorectal, lung, or pancreatic cancer that cannot be removed by surgery (unresectable) or is …
Sponsor: University of Rochester
NCT ID: NCT06073431
Sites in Indiana: - Reid Health — Richmond, Indiana
Recruiting Academic/Other
The iCaRe2 is a multi-institutional resource created and maintained by the Fred \& Pamela Buffett Cancer Center to collect and manage standardized, multi-dimensional, longitudinal data and biospecimens on consented adult cancer patients, h…
Sponsor: University of Nebraska
NCT ID: NCT02012699
Sites in Indiana: - Parkview Research Center — Fort Wayne, Indiana
Recruiting Academic/Other
This clinical trial collects blood, saliva, urine, or stool samples to help identify possible genetic mutations that may increase a person's chance at developing pancreatic cancer. Finding genetic markers among pediatric patients with acut…
Sponsor: M.D. Anderson Cancer Center
NCT ID: NCT06651580
Sites in Indiana: - Riley Hospital for Children — Indianapolis, Indiana
Recruiting Industry
This is an observational case-control study to train and validate a genome-wide methylome enrichment platform to detect multiple cancer types and to differentiate amongst cancer types. The cancers included in this study are brain, breast, …
Sponsor: Adela, Inc
NCT ID: NCT05366881
Sites in Indiana: - Baptist Floyd — New Albany, Indiana
Recruiting Academic/Other
The study schema is shown in Figure 4. (A) All patients referred to one of the participating academic centers for EUS evaluation of the PCL will be enrolled in the protocol if they satisfy inclusion criteria. Patient consent will be obtain…
Sponsor: Ohio State University Comprehensive Cancer Center
NCT ID: NCT03492151
Sites in Indiana: - Parkview Hospital Randallia — Fort Wayne, Indiana
Recruiting Academic/Other
The Coordinating and Data Management Center (CDMC) at MD Anderson Cancer will be responsible for the coordination and data management for the Evaluation of a mixed meal test for Diagnosis and characterization of Type 3c diabetes mellitus s…
Sponsor: M.D. Anderson Cancer Center
NCT ID: NCT03460769
Sites in Indiana: - Indiana University — Carmel, Indiana
NA Recruiting Academic/Other
The goal of this study is to test whether chemotherapy guided by a new imaging method named DCE-MRI can more effectively reduce a pancreatic tumor, enabling curable surgery, over the conventional method when a tumor is categorized as borde…
Sponsor: Ohio State University
NCT ID: NCT06173310
Sites in Indiana: - Indiana University Medical Center — Indianapolis, Indiana